Empower $EPW $EPWCF is an integrated healthcare company - serving patients through medical centers, a medical device company and a high complexity medical diagnostics laboratory.  More than just lip service, here are their latest financial results:

2021 Annual Revenue $4.37M - Up 355% vs 2020

• 2021 Annual Revenue $4.37M  Up 355% vs 2020
• Q1-22 Revenue $1,106,950  Gross margin 21%
• Q2-22 Revenue $1,553,980 Gross margin 47%
• Q3-22 Revenue $1,573,809 Gross margin 59%
• Q4-22 Revenue $426,786 Gross margin 16%

BUILDING A SCALABLE, INTEGRATED HEALTHCARE COMPANY.

$EPW is generating these results from an ecosystem of medical divisions across North America that are both complementary and forming the basis of a much larger expansion into the US market, as follows:

• Medisure Laboratory -  High complexity lab providing diagnostic and testing services
• MediSure Canada -  A leading At-home diagnostics testing & medical device company
• The Medi-Collective - Clinics providing multi-disciplinary group of medical practitioners 

LETTER OF INTENT TO LAUNCH US CLINICAL TRIAL MANAGEMENT SERVICES FOR BIOTECH AND PHARMACEUTICAL INDUSTRIES

If preparation is the key to success, then the building of a scalable, integrated healthcare company over the last 3 years is precisely the reason for this major announcement last month. Empower Signed Letter of Intent for Partnership to Launch US Clinical Trial Management Services for Biotech and Pharmaceutical Industries.

The partnership with renowned Dr. Mocherla will leverage the $EPW lab in Dallas to serve the clinical trials market.  Specifically, the partnership 

$USD 76 BILLION MARKET OPPORTUNITY GROWING TO $127 BILLION BY 2028

To say the market for helping the biggest pharmaceutical and biotech companies in the world run clinical trials is massive is an understatement.  The CRO Services Market is estimated to be worth $76.6 billion in 2023 and poised to reach $127.3 billion by 2028, growing at a CAGR of 10.7% according to a new report by MarketsandMarkets.

If you’re wondering how long it might take for the partnership to crack this nut,  CEO McAuley during our interview stated he expects to get to revenues “quick”.

JOINT VENTURE TERMS SUPPORT CEO EXPECTATION OF “GETTING TO REVENUES QUICK”

We’ve all seen our share of Joint Ventures in which companies are actually looking to throw spaghetti at the wall and see what sticks.  But the terms of this JV indicate the partners are very serious and have high expectations:

• $US 200,00 Seed Capital Contributed By Each Partner To The JV 
• 2 Million Shares Of $EPW Issued To Dr. Mocherla. 
• Upon Achieving $US 5M Revenue, $EPW To Grant 750,000 Stock Options To Mocherla

What did Steven McAuley, Chairman and CEO of Empower have to say?

"This is a transformational partnership for Empower Clinics. Despite the global economic headwinds, the pharmaceutical and biotech industries continue to see strong growth and investment in R&D. Our diagnostics laboratory in Dallas serves as the perfect hub to launch US SMO services with the guidance of Dr. Mocherla. From there we can continue to launch additional SMO sites throughout US and Canada by leveraging Empower's network of health professionals and our unique access to capital markets as a public company."

Today, the company announced that it is Advancing Partnership with Formation of Delaware Based Company and Identification of Principal Investigators

Partnership with Dr. Bharat Mocherla rapidly accelerates in first 30 days with formation of Delaware Joint Venture Company and identification of 50+ principal investigator candidates.

Steven McAuley, Chairman and CEO of Empower commented further: 

"This is a significant step forward in the first 30 days from first announcing our LOI with Dr. Mocherla and serves as a clear indication of our mutually shared intention to rapidly proceed forward with the business of operating a Site Management Organization. This intention is fueled by the fact that both Empower with its Dallas facility, clinics, patient management expertise and access to capital markets, and Dr. Mocherla with big pharma relations and research expertise, bring together the elements necessary to achieve scale in the massive and growing industry of clinical trial management services."

Now sit back, relax and watch this powerful interview.